Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The Phase 2 1 mg arm is the strongest microdose evidence in the GLP-1 class direct measurement, not extrapolation
OVER 100,000 TREES PLANTED AND COUNTING
10.2174/1568026013394741 Curr
Significantly liver or kidney impaired
The objective of this study was to determine whether these NEXT GENERATION (NGEN) HepQuant Tests, using Risk ACE as endpoint, could detect treatment effects in MAESTRO-NAFLD-1 (NCT04197479), an open label, single arm study of resmetirom, a thyroid hormone receptor- agonist being studied for the treatment of NASH (Harrison et al., Lancet 2019, 394:2012-24)
)
US$ 22.73
US$ 27.70
US$ 23.44
US$ 28.76
US$ 24.30
